Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.46 |
| ▸ | F13A1 | P00488 | 3/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13544025 | 0.88 | KEAP1 (0.44) | CYSLTR2CYSLTR1CYP4F2CYP4A11 | |
| SCHEMBL10203390 | 0.86 | MAPT (0.54) | CYSLTR2CYSLTR1MAPTRXFP1LTB4R | |
| SCHEMBL10289860 | 0.82 | MAPT (0.61) | CYSLTR2CYSLTR1MAPTRXFP1LTB4R | |
| SCHEMBL12086495 | 0.81 | LTB4R (0.63) | CYSLTR2CYSLTR1MAPTRXFP1LTB4R | |
| SCHEMBL27262058 | 0.81 | CYSLTR2 (0.68) | CYSLTR2CYSLTR1 | |
| SCHEMBL25170031 | 0.81 | CYSLTR2 (0.68) | CYSLTR2CYSLTR1 | |
| SCHEMBL22826566 | 0.80 | MAPT (0.67) | CYSLTR2CYSLTR1MAPTRXFP1LTB4R | |
| SCHEMBL10203389 | 0.80 | HDAC3 (0.52) | CYSLTR2CYSLTR1MAPTRXFP1 | |
| SCHEMBL13491999 | 0.79 | MAPT (0.57) | CYSLTR2CYSLTR1MAPTRXFP1LTB4R | |
| SCHEMBL9529521 | 0.78 | FFAR4 (0.69) | CYSLTR2CYSLTR1LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | CYSLTR2 2705/4885CYSLTR1 1922/4885MAPT 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.